Hepatobiliary and Liver Transplant Surgery, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
Clin Transplant. 2013 Jul-Aug;27(4):555-61. doi: 10.1111/ctr.12150. Epub 2013 Jun 13.
Recurrent hepatocellular carcinoma (HCC) following liver transplantation (LT) carries a poor prognosis. The aim of our study was to assess the safety and efficacy of sorafenib in patients with recurrent HCC following LT.
A prospectively maintained LT database was retrospectively analyzed for patients with recurrent HCC following LT between 2001 and 2011-34 patients. Patients were divided into two groups based on whether they were prescribed sorafenib (n = 17) or not prescribed sorafenib (n = 17). The primary endpoint was overall survival.
There were no significant differences between the two groups analyzed. Seventeen patients were on sorafenib for recurrent HCC, with a mean daily dose of ~444 mg. Mean duration of treatment was ~10 months. Side effects included: thrombocytopenia, diarrhea, rising transaminases, fatigue, hand-foot skin reaction, and nausea. Survival in the sorafenib vs. non-sorafenib group was greater at three-, six-, nine-, and 12-month intervals and overall survival.
Sorafenib can be well tolerated and safe in patients with recurrent HCC following LT and may be associated with a modest survival benefit. To our knowledge, this is the largest single-center retrospective analysis of patients prescribed sorafenib for recurrent HCC after LT.
肝移植（LT）后复发性肝细胞癌（HCC）预后不良。我们的研究旨在评估索拉非尼在 LT 后复发性 HCC 患者中的安全性和疗效。
回顾性分析 2001 年至 2011 年期间 LT 后复发性 HCC 的前瞻性 LT 数据库-34 例患者。根据是否开具索拉非尼（n = 17）将患者分为两组。主要终点是总生存。
两组分析无显着差异。17 例患者因复发性 HCC 服用索拉非尼，平均日剂量约为 444mg。平均治疗时间约为 10 个月。副作用包括血小板减少、腹泻、转氨酶升高、疲劳、手足皮肤反应和恶心。索拉非尼组与非索拉非尼组在 3、6、9 和 12 个月以及总生存时间的生存率更高。
索拉非尼可耐受良好，安全性好，LT 后复发性 HCC 患者可能有适度的生存获益。据我们所知，这是最大的单中心回顾性分析 LT 后接受索拉非尼治疗复发性 HCC 的患者。
